If lifestyle beat metformin in DPP, why would anyone take the 850 mg tablet for prevention?
850 mg reviews that count UKPDS events, not pounds
Open a cart review and you will hear 'lost ten pounds'. Open UKPDS 34 and you will hear endpoints.
Metformin drops HbA1c by roughly one to one-and-a-half percentage points. Used alone it almost never causes hypoglycaemia. It is weight-neutral to mildly weight-reducing. Those traits make it a sensible opening move. They do not make it a slimming SKU. The GLP-1 agonists produce large, dedicated weight-loss trials. Metformin does not. Anyone swallowing an 850 mg chip mainly to thin down is reading the wrong poster.
What moved guidelines from 'tolerable cheap tablet' to 'start here' was not a forum before-and-after. It was UKPDS 34 in 1998, then the prevention data below. Major diabetes societies still name metformin the preferred initial drug for most people with type 2 diabetes, and it usually stays in the regimen when a newer agent is layered on. The labeled pharmacology behind that glucose drop sits in the Glucophage 850 mg monograph.
UKPDS 34: 342 overweight adults, events on the primary line
The United Kingdom Prospective Diabetes Study ran newly diagnosed type 2 diabetes across 23 UK centres from 1977. In 15 of those centres, overweight patients - more than 120 percent of ideal body weight - could be randomised to metformin. The primary comparison in UKPDS 34 was 342 people on intensive metformin versus 411 on conventional diet-first care. Median follow-up was 10.7 years. Mean HbA1c landed at 7.4 percent on metformin and 8.0 percent on conventional care.
Against conventional care, metformin cut any diabetes-related clinical endpoint by 32 percent, diabetes-related death by 42 percent, all-cause mortality by 36 percent, and myocardial infarction by 39 percent. A secondary look against intensive sulfonylurea or insulin in other overweight patients also favoured metformin on the aggregate event line, mortality, and stroke. That is why the tablet became first-line. It hinted the drug was doing more than moving a lab value.
The caveat has to sit on the same blotter. Three hundred and forty-two is not a small n for 1970s diabetes work, but it is not a modern cardiovascular-outcomes trial either. Metformin was in the original protocol for overweight patients only, in 15 of 23 centres. No later study has reproduced the mortality benefit as cleanly. A supplementary add-on of metformin to maximum sulfonylurea in 537 people even associated with more diabetes-related death - a messy, under-powered signal that still keeps honest readers from treating UKPDS as a slogan. Encouraging event data. Not a closed case.
Ten more years of watching did not erase the event cut
When the randomised phase ended, glucose differences faded. The event gap in the metformin arm did not.
Holman and colleagues posted a ten-year post-trial watch in 2008. Between-group HbA1c differences were lost after the first year off protocol. In the overweight metformin group, relative cuts persisted for any diabetes-related endpoint (21 percent), myocardial infarction (33 percent), and death from any cause (27 percent). That is the 'legacy' line people quote. It is real. It is also still the same original 342-versus-411 randomisation, now followed longer.
Microvascular disease did not move the same way in the metformin arm, during the trial or after. The sulfonylurea-insulin intensive group later showed a microvascular cut and a delayed infarct and mortality signal of its own. So the fair post is not 'metformin uniquely saves every organ'. The fair post is: in overweight, newly diagnosed adults, an early metformin policy left an event scar that outlived the HbA1c gap. That is enough to keep the 850 mg chip at the front of most starts. It is not enough to sell it as a heart drug the way empagliflozin or semaglutide can now be sold from dedicated trials.
DPP used 850 mg twice daily. Lifestyle still won.
The Diabetes Prevention Program, posted in 2002, asked a different question: can you keep type 2 diabetes from starting? Knowler's group randomised 3,234 adults with elevated fasting and post-load glucose to placebo, metformin 850 mg twice daily, or an intensive lifestyle program aiming for at least 7 percent weight loss and 150 minutes of activity a week. Mean age 51. Mean BMI 34. Average follow-up 2.8 years.
Incidence was 11.0, 7.8, and 4.8 cases per 100 person-years in placebo, metformin, and lifestyle. Metformin cut progression by 31 percent versus placebo. Lifestyle cut it by 58 percent. To prevent one case over three years you needed about 13.9 people on metformin and 6.9 in the lifestyle program. Lifestyle beat the drug. The 850 mg twice-daily dose in that trial is the same labeled chip this site locks in SERP - used as a prevention tool, not as a slimming cart.
Two limits belong next to the 31 percent. Prevention here mostly means delay: when the tablet stopped, part of the protection faded. And metformin is not FDA-approved for diabetes prevention, so this use, evidence-based as it is, stays off-label. Later DPP follow-up still favoured lifestyle over the long haul. The drug is the runner-up you offer when coaching cannot be staffed the way a trial staffs it. The labeled start and the gut climb for that 850 mg chip are in the dosing journal.
PCOS, pregnancy sugar, and other off-label edges
| Claim you will see | What actually moved | Honest post |
|---|---|---|
| Type 2 glucose control | Large, long, first-line use | Strong. The approved core. |
| Heart and death benefit | UKPDS 34 overweight arm, 342 on drug | Event signal. Not a modern CVOT. |
| Slimming cart | Modest, inconsistent pounds | Not a weight-loss SKU. |
| Diabetes prevention | DPP: 31% vs placebo, 850 mg BID | Real, off-label. Lifestyle won. |
| PCOS | Cycles, ovulation, insulin numbers | Helpful adjunct. Off-label. |
Polycystic ovary syndrome shares a thread with type 2 diabetes: insulin resistance in a large fraction of women. Metformin can regularise cycles, lift ovulation odds, and tidy metabolic numbers. For fertility, letrozole generally outperforms it. For androgen-driven skin and hair, other treatments do more. The role is supporting cast, and it is off-label in the United States. That is still a reasonable clinic use. It is not a second approved indication hiding in the carton.
Gestational diabetes and antipsychotic weight-gain blunting sit in the same drawer: trial-supported in places, used widely, still outside the US type 2 label. None of those edges should be sold as if they carried UKPDS event weight. The plant-to-pill file that explains why the class even survived is the goat's rue trace.
SGLT2 and GLP-1 outrun it on dedicated heart and kidney files
First-line is not 'strongest on every axis'. The 850 mg chip lost that contest years ago.
| Axis | Metformin 850 mg class | Sulfonylurea | SGLT2 | GLP-1 |
|---|---|---|---|---|
| HbA1c | ~1 to 1.5% | ~1 to 1.5% | ~0.5 to 0.8% | ~1 to 1.5% |
| Weight | Neutral / slight loss | Gain | Loss | Loss |
| Hypoglycaemia alone | No | Yes | No | No |
| Dedicated CV trial | No (UKPDS events) | No | Yes | Yes |
| Cost | Very low | Low | Higher | Higher |
Line metformin up against a sulfonylurea and it wins on what patients feel: no weight gain, no lone-drug hypoglycaemia. Line it up against an SGLT2 inhibitor or a GLP-1 receptor agonist and the newer classes win on proven cardiovascular and kidney endpoints plus weight. Those benefits come from dedicated outcome trials. UKPDS was not built as a modern MACE study. Pretending otherwise is how a review turns into a cart.
So why does the cheap tablet keep the front slot? Cost, gut-manageable safety, and decades of mapped behaviour. The modern move is usually keep metformin and add the newer agent when heart failure, atherosclerotic disease, or chronic kidney disease is the reason you are in the room. Swap-out happens. Foundation-plus is more common. The practical climb that keeps people on the foundation is in the eGFR and gut journal.
What an 850 mg review owes the reader
A fair review says: solid glucose drop, excellent price, rare lone-drug lows, a real UKPDS event signal in overweight new diagnoses, a real DPP delay at 850 mg twice daily, and a modest weight nudge that should not be the reason you start. An unfair review says: 'this is the weight-loss pill doctors hide' or 'proven to save every heart'. The first set is enough. The second set is a cart.
The overstatement slips in when 342 people become a slogan, when lifestyle's 58 percent is memory-holed, or when PCOS is treated as if it sat on the FDA label. Read the event file. Ignore the slimming pitch. Then decide whether the 850 mg chip is your foundation or someone else's leftover story. Primary trial pages worth a nofollow look: the Lancet UKPDS 34 abstract and the NEJM DPP paper.
Reader mail
Reader questions on this article
Answered by Dr. Nathan Whitfield, MD · Internal medicine & clinical pharmacology
Readers argued with the event file. These answers stay on the numbers.
Because most people do not get a trial-grade coach. DPP's lifestyle arm aimed at 7 percent weight loss and 150 minutes a week with staff that ordinary clinics cannot copy. That arm cut progression 58 percent. Metformin 850 mg twice daily cut it 31 percent. Lifestyle won. The tablet is what you offer when the coaching cannot be staffed, or when a younger, heavier person with a very high fasting glucose needs a second tool. Prevention is still off-label in the US. I would not start the chip as a slimming project. I would start it as a delay tool next to whatever lifestyle the person can actually keep.
You keep calling UKPDS a limited arm. Should I distrust the heart claim?
Weight it. Do not bin it. UKPDS 34 randomised 342 overweight adults to metformin and 411 to conventional diet-first care. Events fell: 32 percent on the aggregate diabetes endpoint, 39 percent on infarcts, 36 percent on all-cause death. That moved guidelines. It was not a modern dedicated cardiovascular-outcomes trial, and no later study has copied the mortality cut as cleanly. The ten-year watch still showed a legacy gap after HbA1c differences faded. So I say: probable event benefit in overweight new diagnoses, not a settled 'heart drug' slogan. SGLT2 and GLP-1 agents now have cleaner heart files if that is the reason you are choosing.
I have PCOS, not diabetes. Why is an 850 mg diabetes chip on my list?
Insulin resistance sits in the middle of a lot of PCOS. Metformin can tidy that, which sometimes regularises periods and lifts ovulation odds. If fertility is the goal, letrozole usually outperforms it. If hair and skin are the goal, other treatments do more. This is off-label. It is still a reasonable adjunct, not a carton indication. I would not sell you the 850 mg chip as a PCOS cure or as a weight-loss plan. I would sell it as a metabolic helper that may or may not move the symptom you actually care about. Give it a few months with food and a slow climb before you judge.
With the new injections, is the cheap 850 mg tablet outdated?
Outranked on some axes. Not outdated. GLP-1 agonists and SGLT2 inhibitors have dedicated heart and kidney trials and real weight loss. If you already have heart failure, atherosclerotic disease, or significant kidney disease, those drugs may matter more for the outcome you fear. Metformin stays as the foundation because it is cheap, it does not drop sugar alone, and we have decades of mapped behaviour. The usual modern move is keep the 850 mg climb and add the newer agent. Swap-out happens when the gut will not settle or eGFR falls through the floor. Foundation-plus is still the common post.
Forum reviews swear I will lose a stone. Is that the UKPDS signal?
No. That is the cart. UKPDS counted infarcts, diabetes events, and deaths. Weight in that program was a side observation, not the primary line. Metformin is weight-neutral to mildly reducing. Some people lose a few pounds from appetite and gut effects. Many do not. A stone is a GLP-1 story, not an 850 mg metformin story. If a review leads with a transformation photo, flag it. If it leads with HbA1c and whether the person still has a stomach, it is closer to the file. I would rather you be pleasantly surprised by a small loss than bitterly surprised by a missing one.
Is the 850 mg twice-daily DPP dose the same as a diabetes start?
Same chip, different job. DPP used 850 mg twice daily - 1700 mg a day - in people who did not yet have diabetes. A typical type 2 start on the US label is 500 mg twice daily or 850 mg once daily with meals, then a climb by 500 mg weekly or 850 mg every two weeks toward 1500 to 2000 mg, ceiling 2550 mg immediate-release. You do not open prevention or treatment at 1700 mg on day one unless a clinic has a specific reason and a settled gut. The labeled ladder is in the climb journal. The 850 mg number this site locks is the labeled IR strength, not a dare.
Did adding metformin to a sulfonylurea in UKPDS actually look harmful?
In one supplementary randomisation, yes, and it is the line honest reviews should not hide. Among 537 people already on maximum sulfonylurea, early add-on metformin associated with more diabetes-related death than staying on the sulfonylurea alone. The interval was wide and the sample was not the main 342-person arm. It has not driven metformin off the market. It has kept people from treating every UKPDS sentence as a blessing. Combination care is routine now, with better drugs in the stack. I still would not quote UKPDS as 'metformin plus anything is safer'.
Why do societies still put metformin first if other drugs drop sugar as much?
Because first-line is a bundle, not a single millimetre on an HbA1c strip. The 850 mg class matches a sulfonylurea on glucose and beats it on weight and lows. It is cheaper than the new injectables. Its behaviour is mapped in hundreds of millions of people. That mix is hard to beat as an opening move when the person in front of you does not yet have a heart-failure or kidney reason to jump to an SGLT2 or GLP-1. Those agents get layered in as the situation demands. The event file that still props the opening move is UKPDS 34, not a shopping review.
Where can I read the actual trials without a cart in the margin?
Primary sources, not a marketplace. UKPDS 34 is the 1998 Lancet paper on intensive metformin in overweight new diagnoses. The ten-year watch is Holman 2008 in the New England Journal. DPP is Knowler 2002 in the same journal, metformin 850 mg twice daily versus lifestyle versus placebo. The US label for strengths, food, and eGFR is on DailyMed. I link the Lancet and NEJM pieces in the journal above with nofollow. For this site's own labeled card, use the Glucophage 850 mg monograph. If a page leads with a discount code, you are not in the event file anymore.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated